.png)
MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
55W 14th St Ste 101, Helena, Montana, 59601, US
+1(406)-319-1601
news.in.usa@olahost.top
Copyright © 2024 olascience. All Rights Reserved
